- Home
- MDWD vs DHY Comparison
MDWD vs DHY Comparison
Compare MDWD & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- DHY
- Stock Information
- Founded
- MDWD 2000
- DHY 1998
- Country
- MDWD Israel
- DHY United States
- Employees
- MDWD N/A
- DHY N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- DHY Finance/Investors Services
- Sector
- MDWD Health Care
- DHY Finance
- Exchange
- MDWD Nasdaq
- DHY Nasdaq
- Market Cap
- MDWD 208.2M
- DHY 220.7M
- IPO Year
- MDWD 2014
- DHY N/A
- Fundamental
- Price
- MDWD $18.63
- DHY $2.12
- Analyst Decision
- MDWD Strong Buy
- DHY
- Analyst Count
- MDWD 2
- DHY 0
- Target Price
- MDWD $35.00
- DHY N/A
- AVG Volume (30 Days)
- MDWD 66.7K
- DHY 569.1K
- Earning Date
- MDWD 08-14-2025
- DHY 01-01-0001
- Dividend Yield
- MDWD N/A
- DHY 9.10%
- EPS Growth
- MDWD N/A
- DHY N/A
- EPS
- MDWD N/A
- DHY N/A
- Revenue
- MDWD $19,213,000.00
- DHY N/A
- Revenue This Year
- MDWD $20.64
- DHY N/A
- Revenue Next Year
- MDWD $25.71
- DHY N/A
- P/E Ratio
- MDWD N/A
- DHY N/A
- Revenue Growth
- MDWD N/A
- DHY N/A
- 52 Week Low
- MDWD $14.14
- DHY $1.77
- 52 Week High
- MDWD $22.51
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- MDWD 41.12
- DHY 49.32
- Support Level
- MDWD $17.60
- DHY $2.11
- Resistance Level
- MDWD $19.12
- DHY $2.14
- Average True Range (ATR)
- MDWD 0.79
- DHY 0.02
- MACD
- MDWD -0.15
- DHY -0.00
- Stochastic Oscillator
- MDWD 37.84
- DHY 60.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.